CBRE vs Eli Lilly Which Is Superior?

CBRE Group Inc. and Eli Lilly and Company are two companies that operate in very different sectors. CBRE is a commercial real estate services and investment firm, while Eli Lilly is a pharmaceutical company. Both stocks have performed well in recent years, with CBRE benefiting from a strong commercial real estate market and Eli Lilly seeing success with its innovative pharmaceutical products. Investors looking for diversification in their portfolio may consider investing in both CBRE and Eli Lilly stocks to take advantage of their respective strengths.

CBRE or Eli Lilly?

When comparing CBRE and Eli Lilly, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between CBRE and Eli Lilly.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. CBRE has a dividend yield of 0.0%, while Eli Lilly has a dividend yield of 0.66%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. CBRE reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Eli Lilly reports a 5-year dividend growth of 14.97% year and a payout ratio of 54.12%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with CBRE P/E ratio at 43.89 and Eli Lilly's P/E ratio at 84.95. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. CBRE P/B ratio is 4.84 while Eli Lilly's P/B ratio is 49.93.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, CBRE has seen a 5-year revenue growth of 0.65%, while Eli Lilly's is 0.81%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with CBRE's ROE at 11.41% and Eli Lilly's ROE at 65.15%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $136.02 for CBRE and $773.49 for Eli Lilly. Over the past year, CBRE's prices ranged from $82.75 to $142.00, with a yearly change of 71.60%. Eli Lilly's prices fluctuated between $561.65 and $972.53, with a yearly change of 73.16%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.